Exonics Therapeutics has developed SingleCut CRISPR, a gene repair technology that has the potential to effectively halt the progression of certain genetic neuromuscular diseases. In multiple Duchenne muscular dystrophy preclinical models, Exonics has used SingleCut CRISPR to genetically repair and restore dystrophin, the key protein missing in children with Duchenne. Exonics is initially focused on correcting mutations that cause Duchenne in order to develop a therapy to treat many children with the devastating disease, for which there is no cure.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/09/17 | $40,000,000 | Series A |
The Column Group | undisclosed |
